Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA act mut Dactolisib ovarian clear cell adenocarcinoma sensitive detail...
TP53 mutant DS-7423 ovarian clear cell adenocarcinoma decreased response detail...
PIK3CA C420R DS-7423 ovarian clear cell adenocarcinoma sensitive detail...
PIK3CA E545V DS-7423 ovarian clear cell adenocarcinoma sensitive detail...
PIK3CA H1047R TP53 S90fs DS-7423 ovarian clear cell adenocarcinoma decreased response detail...
TP53 S241F DS-7423 ovarian clear cell adenocarcinoma decreased response detail...
TP53 R175H DS-7423 ovarian clear cell adenocarcinoma decreased response detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT01914510 Phase II ENMD-2076 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed CAN 0
NCT02068794 Phase Ib/II MV-NIS MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Active, not recruiting USA 0
NCT02315430 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed USA 0
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Active, not recruiting USA | ITA | GBR | ESP 2
NCT03602859 Phase III Dostarlimab-gxly + Niraparib Niraparib A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) Active, not recruiting USA | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL 2
NCT04065269 Phase II Ceralasertib + Olaparib Ceralasertib ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) Recruiting GBR | CAN 0
NCT04498117 Phase III Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (FLORA-5) Active, not recruiting USA | ITA | HUN | ESP | CZE | CAN | BRA | BEL | ARG 5